Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
51.53
-0.75 (-1.43%)
At close: May 8, 2026, 4:00 PM EDT
51.91
+0.38 (0.74%)
Pre-market: May 11, 2026, 7:45 AM EDT

Supernus Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2,9912,8562,0161,5841,9351,553
Market Cap Growth
70.92%41.67%27.28%-18.16%24.62%16.75%
Enterprise Value
2,6472,5771,5891,3621,9121,634
Last Close Price
51.5349.7036.1628.9435.6729.16
PE Ratio
--73.0927.391447.0034.3029.76
Forward PE
19.5919.3319.6515.3430.8415.73
PEG Ratio
0.711.111.111.111.111.11
PS Ratio
3.853.973.052.612.902.68
PB Ratio
2.782.691.951.722.181.90
P/TBV Ratio
2.732.641.951.742.481.94
P/FCF Ratio
36.3662.0911.7714.3316.6212.42
P/OCF Ratio
35.9260.3311.7214.2616.5712.22
EV/Sales Ratio
3.413.582.402.242.872.82
EV/EBITDA Ratio
21.5988.029.8117.1114.5213.77
EV/EBIT Ratio
104.58-41.3819.46-258.5041.4518.99
EV/FCF Ratio
32.1956.049.2812.3216.4213.06
Debt / Equity Ratio
0.030.030.030.040.490.52
Debt / EBITDA Ratio
0.821.040.170.423.333.55
Debt / FCF Ratio
0.370.660.160.303.763.36
Net Debt / Equity Ratio
-0.33-0.26-0.41-0.24-0.030.10
Net Debt / EBITDA Ratio
-9.58-9.51-2.63-2.78-0.180.68
Net Debt / FCF Ratio
-4.30-6.05-2.49-2.01-0.200.65
Asset Turnover
0.530.510.500.410.390.36
Inventory Turnover
0.971.091.180.990.981.12
Quick Ratio
1.511.472.041.380.911.55
Current Ratio
1.961.902.351.701.071.91
Return on Equity (ROE)
-2.71%-3.68%7.55%0.15%7.13%6.85%
Return on Assets (ROA)
-2.41%-3.47%4.66%-0.17%2.72%3.93%
Return on Invested Capital (ROIC)
-4.19%-6.34%8.45%-0.28%4.41%6.36%
Return on Capital Employed (ROCE)
-5.39%-5.69%7.92%-0.53%3.86%6.54%
Earnings Yield
-0.97%-1.37%3.65%0.07%2.92%3.36%
FCF Yield
2.75%1.61%8.49%6.98%6.02%8.05%
Buyback Yield / Dilution
-1.57%-0.88%-0.81%10.01%-13.47%-1.24%
Total Shareholder Return
-1.57%-0.88%-0.81%10.01%-13.47%-1.24%
Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q